Weave Bio raises $20M Series A to accelerate pharma regulatory workflows
Weave Bio, a software platform that automates regulatory paperwork for drug development, raised a $20 million Series A, CEO Brandon Rice tells Axios Pro exclusively.
The software startup operates in a booming space for AI-powered drug development tools — but claims its early entry gives it an edge.
-
Weave Bio, a San Francisco-based company redefining regulatory automation through artificial intelligence, has raised $20 million in Series A funding, bringing its total capital raised to $36 million. The round was led by USVP, with additional participation from Innovation Endeavors, Magnetic Ventures, Character, TMV, and Serrado Capital.
The funding marks a significant step for Weave Bio, which has rapidly become a leader in AI-driven regulatory workflow management for the pharmaceutical and biotechnology industries. The company plans to use the new capital to enhance its platform capabilities, grow its commercial operations, and expand globally to meet the evolving needs of the life sciences sector.
Weave Bio’s AI-native platform supports the full lifecycle of regulatory workflows for drug development — from preclinical and clinical stages to post-market updates. The system integrates AI into every stage of the process, including data organization, document authoring, review, publishing, and responses to health authority inquiries. This allows pharmaceutical companies, biotech firms, CROs, and regulatory consultants to manage complex dossiers more efficiently, reducing time, costs, and risk of human error.
The company intends to use the new funding to strengthen its position as a global leader in regulatory technology. The investment will allow Weave Bio to complete end-to-end lifecycle coverage of therapeutic regulatory processes, expand beyond the U.S. to markets such as Europe, Japan, and Latin America, and develop advanced AI tools to support strategic decision-making across drug development portfolios.
Founded in 2022, Weave Bio has quickly gained recognition for its innovative approach, winning “Biotech AI Innovation of the Year” for its success in streamlining preclinical IND preparation. The platform is credited with accelerating regulatory timelines by over 50% while maintaining compliance with global health authority standards, including the FDA and EMA.
Weave’s growth reflects a broader transformation in how regulatory teams operate. Historically, regulatory workflows have relied on manual, time-intensive processes. Weave Bio’s approach replaces those with intelligent automation that prioritizes both accuracy and speed, creating a “human-in-the-loop” system that blends AI efficiency with expert oversight.
